Neuroscience
From Sunday's New York Times:
Daring to Think Differently About Schizophrenia
By ALEX BERENSON
Published: February 24, 2008
"A new drug aimed at treating schizophrenia turns its focus away from dopamine and instead on the effects of glutamate, another powerful neurotransmitter."
[ ... Read the article ... ]
- Family Fortunes
Just read an article in the New Scientist which discussed the apparent link between stress and the inheritance of psychiatric disorders such as schizophrenia and depression. A few recently published studies have shown that stress in the early life...
- Glutamate Agonist Ly2140023: A New Treatment For Schizophrenia?
High hopes for new schizophrenia drugs Drug trial hailed as first major breakthrough for 50 years. By Alison Abbott . . . The side effects of LY2140023, including insomnia and emotional instability, are slightly different to those of olanzapine although...
- Vegetative States
From last Sunday's New York Times Sunday Magazine: A Drug That Wakes the Near Dead By JENEEN INTERLANDI 04 December 2011 "A surprising drug has brought a kind of consciousness to patients once considered vegetative — and changed the debate over...
- Clinical Trials: Evp-6124 Phase 2b Clinical Trial In Schizophrenia
From Drug Discovery & Development: Positive Study Results for Schizophrenia Drug Drug Discovery & Development December 05, 2011 "EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable...
- Fda: Saphris (asenapine) Approval, Schizophrenia And Bipolar
From the FDA: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat...
Neuroscience
Drug Development: Glutamate and Schizophrenia
From Sunday's New York Times:
Daring to Think Differently About Schizophrenia
By ALEX BERENSON
Published: February 24, 2008
"A new drug aimed at treating schizophrenia turns its focus away from dopamine and instead on the effects of glutamate, another powerful neurotransmitter."
[ ... Read the article ... ]
- Family Fortunes
Just read an article in the New Scientist which discussed the apparent link between stress and the inheritance of psychiatric disorders such as schizophrenia and depression. A few recently published studies have shown that stress in the early life...
- Glutamate Agonist Ly2140023: A New Treatment For Schizophrenia?
High hopes for new schizophrenia drugs Drug trial hailed as first major breakthrough for 50 years. By Alison Abbott . . . The side effects of LY2140023, including insomnia and emotional instability, are slightly different to those of olanzapine although...
- Vegetative States
From last Sunday's New York Times Sunday Magazine: A Drug That Wakes the Near Dead By JENEEN INTERLANDI 04 December 2011 "A surprising drug has brought a kind of consciousness to patients once considered vegetative — and changed the debate over...
- Clinical Trials: Evp-6124 Phase 2b Clinical Trial In Schizophrenia
From Drug Discovery & Development: Positive Study Results for Schizophrenia Drug Drug Discovery & Development December 05, 2011 "EnVivo Pharmaceuticals announced the analysis of a completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable...
- Fda: Saphris (asenapine) Approval, Schizophrenia And Bipolar
From the FDA: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat...